References
- Abd-El-Moneim NA, Abdelmoneim S, ElAlfy E (2011). Impact of comorbidity, hormonal receptor status and adjuvant chemotherapy plus tamoxifen versus tamoxifen alone on survival of senior breast cancer patients: retrospective study. J Geriatric Oncol, 2, 57.
- Abe H, Mori T, Kawai Y, Tomida K, Kubota Y et al (2014). Feasibility study of docetaxel and cyclophosphamide sixcycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients. Asian Pac J Cancer Prev, 14, 4835-38.
- Salem AAS, Salem MAE, Abbass H (2010). Breast cancer: surgery at the South Egypt Cancer Institute. Cancers, 2, 1771-8 https://doi.org/10.3390/cancers2041771
- Berry DA, Cirrincione C, Henderson IC, et al (2004). Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-Year experience of the CALGB & U.S. Breast Intergroup. Breast Cancer Res Treat, 88,17. https://doi.org/10.1007/s10459-004-6006-2
- Cihan YB (2014). Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy. Asian Pac J Cancer Prev, 15, 4233-38. https://doi.org/10.7314/APJCP.2014.15.10.4233
- Citron ML, Berry DA, Cirrincione C et al (2013). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial/ CALGB 9741. J Clin Oncol, 21, 1431-39.
- Coudert B, Asselain B, Campone M et al (2012). UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for nodepositivebreast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist. 17, 900-9. https://doi.org/10.1634/theoncologist.2011-0442
- Dignam JJ, Dukic V, Anderson SJ et al (2009). Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat, 116, 595-602. https://doi.org/10.1007/s10549-008-0200-5
- El-Bolkainy MN (2000).Topographic pathology of cancer, 2nded. Cairo, National Cancer Institute, Cairo University:87.
- Elatar I.(2001). Cancer registration, NCI Egypt(2001).Cairo, Egypt, National Cancer Institute, 2002 (http://www.nci.edu.eg/ Journal/nci2001%20.pdf, accessed 1 April 2004)
- Faradmal J, Kazemnejad A, Khodabakhshi R, Gohary MR, Hajizadeh E.(2010). Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer. Asian Pac J Cancer Prev, 11, 353-58.
- Gogia A, Raina V, Deo SV et al (2014). Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: Institutional experience. Asian Pacific J Cancer Prev, 15, 1989-92. https://doi.org/10.7314/APJCP.2014.15.5.1989
- Hamza Abbas, Ashraf Elyamany, Mohamed Salem et al (2011). The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med, 4, 35. https://doi.org/10.1186/1755-7682-4-35
- Hassan BA, Yusoff ZB, Hassali MA, Othman SB, Weiderpass E (2012). Impact of chemotherapy on hypercalcaemia in breast and lung cancer patients. Asian Pacific J Cancer Prev, 13, 4373-78. https://doi.org/10.7314/APJCP.2012.13.9.4373
- Hayes DF, Thor AD, Dressler LG et al (2007). HER2 and response to Paclitaxel in node-positive breast cancer. New Engl J Med, 357, 1496-506. https://doi.org/10.1056/NEJMoa071167
- Ibrahim AS, Komodiki C, Najjar K, Rahamimoff R, Tuncer M (2002). Cancer Profile in Gharbiah, Egypt. Methodology and Results; Ministry of Health and Population Egypt and Middle East Cancer Consortium: Cairo, Egypt.
- Kim KJ, Huh SJ, Yang JH et al (2005). Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Jpn J Clin Oncol. 35, 126-33. https://doi.org/10.1093/jjco/hyi039
- Madarnas Y, Mates M, Agbassi C et al (2011). Adjuvant taxane therapy for women with early stage, invasive breast cancer. Evidence based series No.: 1-7 version 2. Toronto (ON): Cancer Care Ontario, 30.
- Mamounas EP, Bryant J, Lembersky B et al (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol, 23, 3686-96. https://doi.org/10.1200/JCO.2005.10.517
- McCredie, M, Coates M, Grulich A (1994).Cancer incidence in migrants to New South Wales (Australia) from the Middle East, 1972-1991. Cancer Causes Contr, 5, 414-21. https://doi.org/10.1007/BF01694755
- Montemurro F , Aglietta M (2009). Hormone receptor-positive early breast cancer: Controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer, 16, 1091-102. https://doi.org/10.1677/ERC-09-0033
- Omar S, Khaled H, Gaafar R et al (2003).Breast cancer in Egypt: A review of disease presentation and detection strategies. East Mediterr Health J, 9, 448-63.
- Peto R, Davies C, Godurin J et al (2012). Early breast cancer trialist's collaborative group (EBCTCG). Lancet, 379, 432-44. https://doi.org/10.1016/S0140-6736(11)61625-5
- Sakr H, Hamed RH, Anter AH, Yossef T (2013).Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome. Med Oncol, 30, 457. https://doi.org/10.1007/s12032-013-0457-3
- Seedhom AE, Kamal NN (2011). factors affecting survival of women diagnosed with breast cancer in El-Minia Governorate, Egypt. Int J Prev Med. 2, 131-38.
- Tai C, Pan CK, Chen CS et al ( 2014). Adjuvant trastuzumab for 6 months is effective in patients with HER2 positive stage II or III breast cancer. Asian Pacific J Cancer Prev, 14, 1981-84. https://doi.org/10.7314/APJCP.2013.14.3.1981
Cited by
- An update on the management of breast cancer in Africa vol.12, pp.1, 2017, https://doi.org/10.1186/s13027-017-0124-y